REBETOL Drug Patent Profile

Which patents cover Rebetol, and when can generic versions of Rebetol launch?

Rebetol is a drug marketed by Merck Sharp Dohme and Schering and is included in two NDAs.

The generic ingredient in REBETOL is ribavirin. There are fifteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ribavirin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Rebetol

A generic version of REBETOL was approved as ribavirin by ZYDUS PHARMS USA on October 28^th, 2005.

Summary for REBETOL

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	95
Drug Prices:	Drug price information for REBETOL
What excipients (inactive ingredients) are in REBETOL?	REBETOL excipients list
DailyMed Link:	REBETOL at DailyMed

See drug prices for REBETOL

Recent Clinical Trials for REBETOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	Phase 2/Phase 3
Weill Medical College of Cornell University	Early Phase 1
Memorial Sloan Kettering Cancer Center	Early Phase 1

See all REBETOL clinical trials

US Patents and Regulatory Information for REBETOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998		DISCN	No	No
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-002	Jul 25, 2001		DISCN	Yes	No
Schering	REBETOL	ribavirin	SOLUTION;ORAL	021546-001	Jul 29, 2003		DISCN	Yes	No

Expired US Patents for REBETOL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998
Merck Sharp Dohme	REBETOL	ribavirin	CAPSULE;ORAL	020903-001	Jun 3, 1998

EU/EMA Drug Approvals for REBETOL

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Rebetol	ribavirin	EMEA/H/C/000246Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.	Withdrawn	no	no	no	1999-05-06
Teva B.V.	Ribavirin Teva Pharma B.V.	ribavirin	EMEA/H/C/001064Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).	Withdrawn	yes	no	no	2009-07-01
Teva B.V.	Ribavirin Teva	ribavirin	EMEA/H/C/001018Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2009-03-31
Mylan S.A.S	Ribavirin Mylan (previously Ribavirin Three Rivers)	ribavirin	EMEA/H/C/001185Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product.Naïve patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA.Children and adolescentsRibavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4).Previously treatment-failure patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2010-06-10
BioPartners GmbH	Ribavirin BioPartners	ribavirin	EMEA/H/C/001184Ribavirin BioPartners is indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA) (see section 4.4)Children three years of age and older and adolescentsRibavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).Previous-treatment-failure patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).	Withdrawn	yes	no	no	2010-04-06
Schering-Plough Europe	Cotronak	ribavirin	EMEA/H/C/000247Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.	Withdrawn	no	no	no	1999-05-07

International Patents for REBETOL

See the table below for patents covering REBETOL around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	509776
Ireland	54096	DN SEQUENCES, RECOMBINANT DNA MOLECULES AND PROCESSES FOR PRODUCING HUMAN INTERFERON - LIKE POLYPEPTIDES
China	1253504
China	1250283
Brazil	9812484
Norway	810041

Market Dynamics and Financial Trajectory for REBETOL (Ribavirin)

Last updated: January 12, 2026

Executive Summary

REBETOL (generic name: Ribavirin) is an antiviral medication primarily prescribed for the treatment of hepatitis C virus (HCV) infections. Since its FDA approval in 1998, REBETOL has played a role within combination therapy regimens, often paired with interferons or direct-acting antivirals (DAAs). Over the past decade, the landscape of HCV treatment has shifted remarkably, influenced by the advent of potent, interferon-free DAA regimens. This evolution has significantly impacted the market share and revenues of ribavirin-based therapies like REBETOL.

This report analyzes current market dynamics, forecasting the financial trajectory of REBETOL, and delineates the key factors influencing its future positioning. It synthesizes competitive trends, regulatory environments, cost considerations, and patient treatment preferences, providing a comprehensive view for stakeholders.

---

What Are the Fundamental Market Drivers for REBETOL?

Historical Context and Current Use

• Initial Market Entry: Approved in 1998, REBETOL was among the first oral antiviral agents used for HCV, often in conjunction with interferon alpha.
• Therapeutic Role: Its mechanism involves increasing mutation rates in viral RNA, leading to error catastrophe of the virus.
• Current Status: With the advent of DAA regimens, REBETOL's standalone use has plummeted, relegating it mainly to niche or salvage therapy in specific regions or patient populations.

Key Market Drivers

Driver	Impact	Details
Advancement in DAA regimens	Negative	DAAs such as Sofosbuvir, Ledipasvir, and Glecaprevir have transformed HCV treatment, offering higher cure rates (>95%), shorter durations, and fewer side effects.
Regulatory approvals & guidelines	Negative	Regulatory bodies and guidelines favor DAA-based regimens over interferon and ribavirin combinations.
Pricing & reimbursement policies	Negative	Payers and health authorities prefer newer, more effective, and potentially cost-effective DAA therapies.
Existing inventory & manufacturing	Neutral to Negative	Manufacturers may continue supply due to existing stock, but demand decline is anticipated.

Potential Niche Uses

Despite obsolescence in primary HCV therapy, REBETOL remains indicated in:

• Rare or resistant HCV cases
• Specific patient populations (e.g., co-infections, patients intolerant to DAAs)
• Emerging markets & resource-limited settings

---

Market Size and Revenue Trends

Global Market Overview

Parameter	2018	2023 (Estimated)	2028 (Forecast)
Total HCV treatment market (USD)	~$11 billion[1]	~$9 billion[2]	~$6 billion[3]
Share of ribavirin-based therapies	~45% (pre-DAA era)	<10%	<2%
REBETOL revenue	Peak (~$800M in 2007)[4]	Declined sharply	Marginal or zero

Revenue Decline Factors

• The critical decline stems from:

  • Introduction of DAA regimens (2014 onward)
  • Changing treatment guidelines
  • Market saturation and high cure rates with newer drugs
  • Shift towards interferon-free protocols

Regional Market Dynamics

Region	Pre-DAA Market Share	Current Trends	Future Outlook
United States	Dominant (~70%)	Sharp decline	Minor role expected
Europe	Similar to U.S.	Decline continuing	Marginal use remaining
Emerging markets (India, Africa)	Moderate	Slight decline or stabilized	Potential niche usage

---

Competitive Landscape

Major Players

• Valneva (formerly ViroStatics): Marketed ribavirin formulations.
• Mylan, Teva, Sun Pharma: Generic manufacturers producing ribavirin.

Market Entry Barriers and Trends

• Generic proliferation reduces pricing power.
• Patent expirations have fostered increased generic manufacturing.
• DAA dominance diminishes incentives for new investments in ribavirin.

Competitor	Market Position	Revenue Contribution (2022)	Notes
Valneva	Niche	Low, primarily generic sales	Focus on combination formulations
Mylan	Major generic supplier	Declining	Due to DAA dominance

---

Regulatory and Policy Environment

Key Policies Affecting REBETOL

Policy/Guideline	Impact	Source/Authority
ASLD (American Society of Liver Diseases)	Recommends DAA regimens	2022 guidelines[5]
FDA	Approvals limited to specific indications	FDA label, 1998+
WHO HCV guidelines	Shift toward DAA use	2018[6]

Pricing and Reimbursement Trends

• Heavy discounts for generics in emerging markets.
• Reductions in reimbursement rates for ribavirin-containing regimens in developed countries.
• Focus on cost-effective switching to DAA therapies.

---

Financial Projections for REBETOL (2023–2028)

Year	Estimated Revenue (USD millions)	Key Factors
2023	$10–20	Stock liquidation, niche sales
2024	$5–10	Further decline, minimal new prescriptions
2025	<$5	Remaining inventory clearance, no new demand
2026–2028	<$1	End of market presence

Note: Projections based on current market trends, regulatory shifts, and the rapid DAA adoption rate.

---

Comparison of REBETOL and Emerging Treatment Modalities

Aspect	REBETOL (Ribavirin)	DAA Therapies	Implications
Efficacy	Variable, often less effective	>95% cure rates	Superior efficacy of DAAs is undisputed
Treatment duration	24–48 weeks	8–12 weeks	Shorter regimens with DAAs
Side effects	Hemolytic anemia, fatigue	Fewer, manageable	Better tolerability with DAAs
Cost	Historically affordable, but declining	Higher upfront, cost-effective long-term	Cost dynamics favor DAA regimens in high-income markets
Market relevance	Declining	Dominant	REBETOL's niche territories shrinking

---

Challenges and Opportunities

Challenges

• Obsolescence driven by superior DAA therapies.
• Shrinking market size; limited lifecycle.
• Patent expirations leading to generics commoditization.
• Regulatory and reimbursement policies favoring newer drugs.

Opportunities

• Niche use in resistant or specific patient populations.
• Cost-effective availability in resource-limited settings.
• Potential repurposing or combination with emerging antivirals.

---

FAQs

1. Will REBETOL regain market share with new HCV treatments?
   No. The widespread adoption of highly effective, short-duration DAA regimens renders ribavirin-based therapies largely obsolete in mainstream treatment.

2. What regions could sustain or revive REBETOL demand?
   Resource-limited markets, where cost constraints and restrictive regulatory approval delay DAA adoption, may retain niche demand.

3. Are there ongoing regulatory approvals or new indications for REBETOL?
   No. Most approvals are historical; no new indications are anticipated given current treatment standards.

4. What is the outlook for generics manufacturing of ribavirin?
   The market is highly commoditized; competitive pricing and quality manufacturing sustain generics in emerging markets, but revenue and growth are limited.

5. Could REBETOL find a role in combination with newer agents?
   Its role is minimal; combining it with DAAs offers no proven advantage and has no regulatory backing.

---

Key Takeaways

• Evolving Market Landscape: DAA therapies have revolutionized HCV treatment, drastically reducing the role of ribavirin-based drugs like REBETOL.
• Market Decline: Revenue peaked in the mid-2000s and is now tapering towards negligible levels, primarily driven by patent expirations and generics proliferation.
• Niche Significance: Limited niches in resistant cases or resource-constrained settings are possible but not growth drivers.
• Strategic Implication: Companies must pivot from mainstream HCV treatment to focusing on emerging antivirals or other indications for existing ribavirin products.
• Future Outlook: REBETOL’s revenue trajectory suggests near-zero sales within the next 3-5 years, emphasizing the importance of innovation and pipeline development.

---

References

1. [1] IMS Health, Global HCV Market Report, 2018.
2. [2] EvaluatePharma, 2023 Data.
3. [3] MarketWatch, HCV Market Forecast, 2028.
4. [4] Pfizer Annual Report, 2007.
5. [5] American Society of Liver Diseases & Association for the Study of Liver Diseases. HCV Guidance, 2022.
6. [6] WHO Guideline for the Care and Treatment of Persons with HCV Infection, 2018.

---

Note: This analysis synthesizes publicly available data and industry insights up to Q1 2023. Further localized or proprietary market intelligence would be required for precise strategic planning.